#JPM22: High­lights for the year ahead in on­col­o­gy R&D — What's hot, what's not?

Across the broad spec­trum of on­col­o­gy drug de­vel­op­ment, 2021 marked a year of break­throughs with off-the-shelf cell ther­a­pies com­ing in­to their own (with some ques­tions) as clas­si­cal­ly “un­drug­gable” tar­gets fell to the in­evitable march of progress.

In 2022, some of the bright­est minds in on­col­o­gy see the po­ten­tial for even more break­throughs — a rev­o­lu­tion in epi­ge­net­ics af­ford­ing even more in­sight in­to the func­tion of the cell, the po­ten­tial for a ma­jor ad­vance in AI-based dis­cov­ery, and even more tar­gets sud­den­ly com­ing avail­able to ther­a­peu­tic in­ter­ven­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.